Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for Hard-to-Treat neuroendocrine tumors?

NCT ID NCT07314164

Disease control Sponsor: Ipsen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 02, 2026 · Updated 4 times

Summary

This study looks at how well the drug cabozantinib works and how safe it is for adults with neuroendocrine tumors (NETs) that have continued to grow after at least one prior treatment. About 150 participants in Germany and Austria will be followed during their routine care. Doctors will track tumor response, side effects, and quality of life to understand the drug's real-world effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

150 adult participants in Austria and Germany who are prescribed cabozantinib tablets for unresectable or metastatic, well differentiated extra-pancreatic (epNET) and pancreatic (pNET) neuroendocrine tumours who have progressed following at least one prior systemic therapy other than somatostatin analogues prior to entry into the study will be included.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Participants can join the study if they meet all of the following conditions: * Are 18 years or older and able to give informed consent. * Have a physician-initiated decision to start treatment with cabozantinib for neuroendocrine tumors (NETs), made before joining the study. * Have unresectable or metastatic, well-differentiated pancreatic (pNET) or extra-pancreatic neuroendocrine tumors (epNET). * Have already received at least one prior systemic therapy, other than somatostatin analogues. * Have signed a written informed consent form. Exclusion Criteria: Participants cannot join the study if: * They are currently participating in an interventional clinical trial, or have done so within the last 3 months before joining this study. * They have a contraindication to cabozantinib treatment, based on the product's official prescribing information.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Neuroendocrine tumors are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

neuroendocrine neoplasm pancreatic neuroendocrine tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Neuroendocrine tumors

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    38 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Asklepios Kliniken Hamburg

    NOT_YET_RECRUITING

    Hamburg, Germany

  • Charité - Universitaetsmedizin Berlin

    RECRUITING

    Berlin, Germany

  • DRK Kliniken Berlin

    RECRUITING

    Berlin, Germany

  • Evangelische Lungenklinik Berlin

    RECRUITING

    Berlin, Germany

  • Gemeinschaftspraxis Haematologie - Onkologie

    RECRUITING

    Dresden, Germany

  • Johannes Wesling Klinikum Minden der Muehlenkreiskliniken AoeR

    RECRUITING

    Minden, Germany

  • Johanniter-Kliniken Bonn

    NOT_YET_RECRUITING

    Bonn, Germany

  • Kepler Universitaetsklinikum GmbH Linz

    NOT_YET_RECRUITING

    Linz, Austria

  • Klinikum Chemnitz

    NOT_YET_RECRUITING

    Chemnitz, Germany

  • Krankenhaus Nordwest

    NOT_YET_RECRUITING

    Frankfurt, Germany

  • Krankenhaus St. Joseph-Stift Bremen GmbH

    RECRUITING

    Bremen, Germany

  • MVZ Leipzig Mitte, MVZ Delitzsch

    NOT_YET_RECRUITING

    Leipzig, Germany

  • MVZ Muelheim an der Ruhr GmbH

    RECRUITING

    Mülheim, Germany

  • MVZ Onkologie Klinikum Osnabrueck GmbH

    NOT_YET_RECRUITING

    Osnabrück, Germany

  • MVZ am Klinikum Aschaffenburg

    RECRUITING

    Aschaffenburg, Germany

  • MVZ fuer Haematologie und Onkologie Koeln am Sachsenring

    RECRUITING

    Cologne, Germany

  • Medizinische Studiengesellschaft Nord-West

    RECRUITING

    Westerstede, Germany

  • Medizinische Universitaet Graz

    RECRUITING

    Graz, Austria

  • Medizinische Universität Wien

    RECRUITING

    Vienna, Austria

  • Philipps-Universitaet Marburg

    RECRUITING

    Marburg, Germany

  • RKH Kliniken Ludwigsburg-Bietigheim gGmbH

    RECRUITING

    Ludwigsburg, Germany

  • Studienzentrum UnterEms

    NOT_YET_RECRUITING

    Leer, Germany

  • TUM Klinikum Muenchen

    NOT_YET_RECRUITING

    München, Germany

  • Technische Univiersitaet (TU) Dresden

    RECRUITING

    Dresden, Germany

  • UKSH Kiel

    NOT_YET_RECRUITING

    Kiel, Germany

  • UKSH Luebeck

    NOT_YET_RECRUITING

    Lübeck, Germany

  • Uniklinikum Frankfurt

    NOT_YET_RECRUITING

    Frankfurt am Main, Germany

  • Universitaestklinikum Saarbruecken

    NOT_YET_RECRUITING

    Saarbrücken, Germany

  • Universitaetsklinikum Erlangen

    NOT_YET_RECRUITING

    Erlangen, Germany

  • Universitaetsklinikum Essen

    RECRUITING

    Essen, Germany

  • Universitaetsklinikum Freiburg

    NOT_YET_RECRUITING

    Freiburg im Breisgau, Germany

  • Universitaetsklinikum Giessen-Marburg

    NOT_YET_RECRUITING

    Giesen, Germany

  • Universitaetsklinikum Hamburg-Eppendorf

    RECRUITING

    Hamburg, Germany

  • Universitaetsklinikum Wuerzburg

    RECRUITING

    Würzburg, Germany

  • Universitaetsmedizin Goettingen

    RECRUITING

    Goettigen, Germany

  • Universiteatsmedizin Leipzig

    NOT_YET_RECRUITING

    Leipzig, Germany

  • Universitätsklinikum Tuebingen

    RECRUITING

    Tübingen, Germany

  • pioh Studien und Mangement GbR

    RECRUITING

    Cologne, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.